Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Hereditary Transthyretin Amyloidosis (ATTRv)Polyneuropathy

Interventions

DRUG

Tafamidis

61 milligrams (mg) as received in studies B3461028 and B3461045

Trial Locations (3)

Hospital Clinico San Carlos, Madrid

Hospital Universitari de Bellvitge, Barcelona

Hospital Son Llatzer, Palma de Mallorca